Methods of preventing inflammation and treating pain using anti-NGF compositions
View Patent ↗Monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.
1. A method of treating pain in an individual, comprising administering a therapeutically effective amount of a humanized anti-human NGF monovalent antibody or antigen-binding fragment thereof comprising the CDR1 sequence of SEQ ID NO:55, the CDR2 sequence of SEQ ID NO:56, and the CDR3 sequence of SEQ ID NO:57, and a variable heavy chain comprising the CDR1 sequence of SEQ ID NO:58, the CDR2 sequence of SEQ ID NO:59, and the CDR3 sequence of SEQ ID NO:60.
2. The method of claim 1 , wherein said monovalent antibody or antigen-binding fragment thereof is a Fab antibody fragment.
3. The method of claim 2 , wherein the Fab antibody fragment is obtained by papain digestion of Ab21.
4. The method of claim 1 , wherein said anti-human NGF antibody or antigen-binding fragment thereof comprises a V L polypeptide comprising the amino acid sequence of SEQ ID NO: 405 and a V H polypeptide comprising the amino acid sequence of SEQ ID NO:406.
5. The method of claim 1 , wherein said anti-human NGF monovalent antibody or antigen-binding fragment thereof specifically binds to NGF expressing human cells and/or to circulating soluble NGF molecules in vivo.
6. The method of claim 1 , wherein said anti-human NGF monovalent antibody or antigen-binding fragment thereof is directly or indirectly attached to a detectable label or therapeutic agent.
7. The method of claim 1 , wherein said anti-human NGF monovalent antibody or antigen-binding fragment thereof further comprises an effector moiety.
8. The method of claim 7 , wherein said effector moiety is a detectable moiety or a functional moiety.
9. The method of claim 8 , wherein said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material.
10. The method of claim 8 , wherein said functional moiety is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material.
11. The method of claim 1 , further comprising the administration of another therapeutic agent or regimen selected from analgesic agents, anti-histamines, antiinflammatory agents or antibiotics.
12. The method of claim 1 , wherein said anti-human NGF monovalent antibody or antigen-binding fragment thereof is contained in a pharmaceutical or diagnostic composition comprising a pharmaceutically acceptable carrier.
13. The method of claim 12 , wherein said pharmaceutical or diagnostic composition further comprises at least one stabilizer.
14. The method of claim 12 , wherein said pharmaceutical or diagnostic composition is lyophilized.
15. The method of claim 1 , wherein the administration is effected via craniofacial mucosal administration, intranasal administration, buccal administration, sublingual administration or conjunctival administration.
16. The method of claim 1 , wherein the anti-human NGF monovalent antibody or antigen-binding fragment thereof is modified in order to enhance in vivo half-life.
17. The method of claim 16 , wherein said modification comprises the addition of at least one water-soluble polymer or alteration of glycosylation.
18. The method of claim 16 , wherein the modification comprises the addition of at least one polyethylene glycol to the anti-human NGF monovalent antibody or antigen-binding fragment thereof.
19. The method of claim 1 , wherein the anti-human NGF monovalent antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intranasally, or transcutaneously.